Highlight
HTD1801 monotherapy led to a robust and statistically significant reduction in HbA1c (-1.3%) compared to placebo (-0.6%) after 24 weeks in patients with inadequately controlled type 2 diabetes. Improvements in key cardiometabolic and inflammatory biomarkers were observed and sustained through 52 weeks. The safety profile was favorable, with predominantly mild to moderate gastrointestinal adverse events occurring early in treatment.
